Interventional Study on the Effects of Forest Therapy in Fibromyalgia Patients
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Azienda USL Toscana Nord Ovest
- Trial code
- NCT07648563
- Record updated
- 15 June 2026
- Original description
The goal of this clinical trial is to evaluate if Forest therapy can reduce pain levels and improve the quality of life related to the level of pain perceived in fibromyalgia patients.Read full original descriptionShow less
A Monocentric, Randomized, Controlled, No-profit, Interventional Study on the Effects of Forest Therapy in Patients With Fibromyalgia
The goal of this clinical trial is to evaluate if Forest therapy can reduce pain levels and improve the quality of life related to the level of pain perceived in fibromyalgia patients.
The main question it aims to answer is:
Does frequenting certified forest environments, according to the principles and methods of Forest Therapy, produce positive effects on chronic pain and the consumption of painkillers? The study is part of the "Forest Therapy Project as a Broad-Spectrum Tool for Patients Affected by Fibromyalgia" funded by the Tuscany Region as part of the Complementary Medicine program for the three-year period 2025-2027. The project will be carried out thanks to the collaboration with the National Research Council - Institute for BioEconomy (CNR-IBE)
Inclusion: 18 years or older; diagnosis of fibromyalgia (diagnosed by a rheumatologist according to ACR criteria); enrolled in the pain management program at the Intensive Care Unit of Cecina Hospital; under treatment with painkillers; without mobility limitations that prevent them from taking slow, easy walks lasting approximately 2.5 hours and covering approximately 2 km, willing to self-certify their ability to walk unassisted in an obstacle-free environment; capable of understanding the purpose of the study and providing informed consent to participate.
Exclusion: Diagnosis of neoplastic disease; Allergies to pollen and/or grasses and/or insect bites; Active systemic disease; Neurological disease; Degenerative disease; Infectious disease; Patients who have not been diagnosed with fibromyalgia; Pregnant women.